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Abstract:  Expression  of  human  granulocyte  macrophage  colony  stimulating  factor 
(hGMCSF), a cytokine of therapeutic importance, as a thioredoxin (TRX) fusion has been 
investigated  in  Escherichia  coli  BL21  (DE3)  codon  plus  cells.  The  expression  of  this 
protein was low when cloned under the T7 promoter without any fusion tags. High yield of 
GMCSF was achieved (~88 mg/L of fermentation broth) in the shake flask when the gene 
was fused to the E. coli TRX gene. The protein was purified using a single step Ni
2+-NTA 
affinity  chromatography and  the column bound fusion tag was removed by on-column 
cleavage with enterokinase. The recombinant hGMCSF was expressed as a soluble and 
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biologically active protein in E. coli, and upon purification, the final yield was ~44 mg/L in 
shake flask with a specific activity of 2.3 ×  10
8 U/mg. The results of Western blot and  
RP-HPLC analyses, along with biological activity using the TF-1 cell line, established the 
identity of the purified hGMCSF. In this paper, we report the highest yield of hGMCSF 
expressed  in  E.  coli.  The  bioreactor  study  shows  that  the  yield  of  hGMCSF  could  be 
easily scalable with a yield of ~400 mg/L, opening up new opportunities for large scale 
production hGMCSF in E. coli. 
Keywords:  human  granulocyte  macrophage  colony  stimulating  factor;  on-column 
cleavage; TRX fusion; IMAC; enterokinase 
 
1. Introduction  
Human granulocyte macrophage colony stimulating factor (hGMCSF) is a cytokine, secreted by 
macrophages,  T  cells,  mast  cells,  endothelial  cells  and  fibroblasts  in  response  to  immune  and 
inflammatory  stimuli.  Mature  human  GMCSF  is  a  glycoprotein  and  consists  of  127  amino  acid 
residues,  with  four  cysteines  being  involved  in  two  disulfide  bonds  [1].  Human  GMCSF  is  an 
important therapeutic cytokine used in the treatment of myeloid leukemia, neutropenia and aplastic 
anemia  [2].  Many  attempts  have  been  undertaken  to  synthesize  biologically  active  recombinant 
hGMCSF;  however,  transfected  mammalian  cells  are  not  preferred  as  an  expression  system  for 
producing GMCSF for biological and structural studies due to low expression levels and the presence 
of contaminating CSFs secreted by the mammalian cells themselves [3]. This problem can be handled 
using an Escherichia coli expression system to produce large quantities of recombinant protein. E. coli 
has widely been used for recombinant protein production [4] due to its ability to grow rapidly and at 
high density on inexpensive substrates, combined with its well-characterized genetics. A variety of 
cloning  and  expression  vectors,  recombinant  fusion  tags  and  mutant  strains  are  available  for 
commercial  manufacture  of  recombinant  proteins  [5,6].  Although  attractive,  some  potential 
disadvantages of this expression system include lack of post translational modifications [7], lack of the 
proper secretion system for efficient release of produced protein into the growth medium, inefficient 
cleavage  of  amino  terminus  methionine  resulting  in  lower  protein  stability  and  increased 
immunogenicity together with the limited ability to facilitate extensive disulfide bond formation and 
improper folding resulting in inclusion body formation [8].  
Protein misfolding or inaccurate processing by cellular molecular chaperones ultimately results in 
formation  of  biologically  inactive  protein.  Hence,  optimization  of  the  expression  conditions  or 
laborious refolding studies is required to achieve an active protein. Also, many eukaryotic proteins 
cannot be expressed successfully in E. coli, and the conventional method to express such proteins is as 
fusion tags [9,10]. There have been reports of expression of hGMCSF as intein fusion entities [11] and 
GCSF fusion proteins [12], with all of them being expressed as insoluble protein aggregates. Soluble 
protein production in E. coli is still a major bottleneck for investigators, and a couple of efforts have 
been reported to improve the solubility or folding of recombinant protein produced in E. coli [13]. 
These include strategies like co-expression of chaperone proteins such as GroES, GroEL, DnaK and Int. J. Mol. Sci. 2011, 12                       
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DnaJ, lowering incubation temperature, use of weak promoters, addition of sucrose and betaine in the 
growth media, use of richer media with phosphate buffer such as terrific broth (TB), use of signal 
sequence to export the protein to the periplasmic fraction and use of fusion tags to aid in expression 
and protein purification [9]. A number of fusion tags are available for the ease of expression and 
purification of recombinant proteins [14,15] and mostly they promote purification of the fused protein, 
though some of them (thioredoxin, NusA, etc.) are also reported to increase the solubility of the target 
proteins in comparison to unfused proteins when overexpressed in  E. coli [16]. In this paper, we 
describe the overexpression of hGMCSF as a soluble thioredoxin (TRX)-fusion and purification to 
homogeneity with very high yield after removal of the fusion tag by enterokinase digestion. 
2. Results and Discussion  
2.1. Cloning and Expression of hGMCSF 
hGMCSF was cloned in pET21a and expressed in BL21 (DE3) codon plus cells in the shake flask 
scale (100 mL LB). As seen in Figure 1a, there was no visible expression of recombinant hGMCSF by 
SDS-PAGE  (upper  panel,  lane  2)  and  the expression  was evident  only  after immunoblot analysis 
(lower  panel,  lane  2).  As  the  poor  expression  of  GMCSF  was  unsuitable  for  any  further 
experimentation, the gene was cloned as a TRX fusion and the expression was carried out in the same 
cell  line  as  described  before.  The  results  shown  in  Figure  1b  indicate  that  the  expression  of  
TRX-GMCSF in soluble form (Figure 1b, lane 2).  Bioreactor study on a 2 L scale (Figure 2) was carried 
out using in-house medium and the total protein in the soluble fraction was found to be 4.95 g/L, which 
corresponds to nearly a yield of 400 mg of crude GMCSF protein/L of fermentation medium. 
2.2. Purification of TRX-hGMCSF Followed by Separation of hGMCSF from the Fusion Tag 
The TRX-GMCSF, containing a six His-tag in between the fusion partners TRX and GMCSF, was 
purified through Ni
2+-NTA sepharose following the protocol described in the Experimental section. 
The  purified  fusion  protein  (Figure  3a,  lane  2)  after  enterokinase  cleavage  and  second  round  of 
purification yielded >95% pure hGMCSF protein (Figure 3a, lane 3) with a final yield of ~44 mg/L 
and  a  fold  purification  of  2.5  (Table  1).  Immunoblot  analysis  with  mouse  monoclonal  
anti-hGMCSF  antibody  confirmed  the  identity  of  the  purified  protein,  which  has  a  theoretical 
molecular mass 14.4 kDa (Figure 3b). The purity of the purified soluble GMCSF from the above 
fusion tag clone following the described method was analyzed by RP-HPLC and SE-HPLC for identity 
and  similarity  study  with  commercial  GMCSF  (Sigma,  U.S.).  RP-HPLC  profiles  of  both  soluble 
hGMCSF  and  commercial  hGMCSF  showed  a  similar  pattern  (Figure  4)  at  a  retention  time  of  
19.797 min with a purity of ~95%, which is better than the commercial protein (~90.2%), indicating 
the efficient separation and purification of the protein of interest. The commercial hGMCSF used was 
procured from Sigma (G 5035) and the product is supplied as a lyophilized powder from a 10 mM 
sodium citrate solution, pH 3.5, with no other proteinous material. This was also evident from the 
profile, with the absence of any major peak other than hGMCSF peak. The SE-HPLC analysis was 
carried out to determine the presence of GMCSF related impurities like aggregation and different 
conformational forms [17]. The chromatogram (Figure 5) shows that the in-house purified hGMCSF is Int. J. Mol. Sci. 2011, 12                       
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~92%  pure  with  no  detectable  aggregation  or  other  conformational  forms,  while  purity  of  the 
commercial GMCSF preparation was found to be relatively less (~86.8%). The biological activity 
assay data indicate that the in-house hGMCSF is more active (potency 1.396) than the commercial 
preparation  (Figure  6)  and  this  could  be  partially  attributed  to  the  better  purity  of  the  in-house 
protein preparation. 
For structural functional and clinical studies, therapeutic proteins in soluble active forms are in 
large demand. Human GMCSF protein has been described to function in the treatment of myeloid 
leukemia, neutropenia and aplastic anemia. Although, different expression systems have been explored 
to express recombinant human GMCSF (such as CHO, yeast, bacteria, etc.), all of them have certain 
degrees of limitations. It has been reported that deglycosylated hGMCSF is at least  20-fold more 
active  than  its  glycosylated  variant  expressed  in  CHO  cells  [18–20].  Similarly,  Saccharomyces 
cerevisae derived GMCSF is clinically unsuitable due to varying degrees of glycosylation [21]. On the 
other  hand,  hGMCSF  expressed  in  E.  coli  has  been  found  to  have  similar  biological  activity  to  
the  native  protein  [22],  indicating  the  non-essentiality  of  glycosylation  for  bioactivity  of  the  
GMCSF protein.  
E. coli expression system offers several advantages like high expression level, rapid growth, simple 
media requirement, etc. Recombinant human GM-CSF produced in E. coli ends up in inclusion bodies 
(IBs) and has certain drawbacks, including complex processing, low specific activity, and poor in vitro 
renaturation [23]. Recently, hGMCSF has been reported to be expressed in E. coli BL21 (DE3) cells 
without IPTG induction as insoluble aggregates [1]. The protein has been purified after solubilization 
and the final yield was found to be ~44 mg/L. Also, intein fusion of hGMCSF has been reported in the 
recent past in E. coli [11] as well as in Pichia [24]. However, hGMCSF expression as a soluble protein 
in E. coli is host dependent, and in both the cases, authors have used dithiothreitol (DTT) to remove 
the  fusion  tag.  Since  DTT  concentrations  above  30  mM  are  known  to  destabilize  the  disulfide  
bonds [25] and use of DTT to remove the fusion tag could hamper the two disulfide bonds that are 
crucial for hGMCSF activity [1], use of DTT in purification of GMCSF using such a strategy appears 
tricky and challenging.  
High GC content and the presence of rare codons in the native human GMCSF gene are reported to 
be causative hurdles in the expression of recombinant human GMCSF (rhGMCSF) in E. coli [26]. In 
order to achieve better expression in E. coli, we have reduced the GC content of the hGMCSF gene at 
the 5' terminus and also used BL21 (DE3) codon plus cells for expression studies to supply rare codons 
required for efficient and optimal expression of the protein.  
Here, we report the soluble expression of hGMCSF in E. coli and on-column cleavage and removal 
of the TRX fusion tag from hGMCSF for the first time. By following the process described in this 
article, we achieved ~95% pure rhGMCSF protein with a specific activity of 2.3 ×  10
8 U/mg with a 
potency of 1.396 as evident from the statistical analysis using the Parallel Line Assay (PLA) software. 
The yield of hGMCSF to ~44 mg/L with a recovery of ~46 % observed in the present study is the 
highest  to  date  [11].  Although  fusion  tags  like  intein  (55  kDa)  have  been  reported  for  GMCSF  
fusions [11], the use of TRX as a fusion tag as described in this paper has an additional advantage. It 
offers higher molar yield of the protein of interest after tag removal since the size of the TRX tag is 
relatively smaller (20 kDa). Our methodology of obtaining soluble GMCSF using the procedure as 
mentioned avoids the cumbersome procedures of refolding and purification of GMCSF from bacterial Int. J. Mol. Sci. 2011, 12                       
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inclusion bodies, making the proposition attractive and user-friendly. Moreover, the expression of 
hGMCSF from the present construct in a bioreactor at 2 L scale yielded ~400 mg/L; thus presenting a 
promising cost-effective alternative for obtaining GMCSF protein in manufacturing scale.  
Table 1. Summary of purification of hGMCSF expressed as TRX fusion from 100 mL 
flask culture. 
Fraction 
Volume 
(mL) 
Protein 
(mg/mL) 
Total Protein 
(mg) 
Total Activity 
(U) 
Specific Activity 
(U/mg) 
Fold Purification  %Yield 
Crude cell lysate  10  2.39  23.9  2.19 ×  10
8  9.16 ×  10
6  1.0  100 
Purified TRX-
GMCSF fusion 
20  0.43  8.6  11.24 ×  10
7  1.3 ×  10
7  1.42  51 
Purified GMCSF  20  0.22  4.4  10.20 ×  10
7  2.3 ×  10
7  2.5  46 
Figure  1.  Expression  analysis  of  pET21a-hGMCSF  and  pET32a-hGMCSF.  (a)  Upper 
Panel: SDS-PAGE analysis of pET21a-hGMCSF expression in BL21 DE3 codon plus cells 
with IPTG induction, showing absence of visible expression. Lane M: molecular weight 
Marker; lane 1: Empty vector control; lane 2: expression from pET21-hGMCSF. Lower 
Panel:  Immunoblot  using  mouse  monoclonal  anti-hGMCSF  antibody  showing  low 
expression level of hGMCSF; (b) SDS-PAGE analysis of TRX-hGMCSF fusion protein 
expression. The pET32a-hGMCSF construct was transformed into BL21 (DE3) codon plus 
cells. The cells were induced with 1 mM IPTG for 3 h. Lane M: Molecular weight Marker; 
lane 1: Crude cell lysate; lane 2: Soluble fraction and lane 3: Insoluble fraction. Arrows 
indicate TRX-GMCSF protein. 
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Figure 2. Expression of TRX-hGMCSF in 2 L fermenter in In-house medium. Various 
fermentation parameters were plotted against the batch hour. The cells were induced with 
1 mM IPTG at an OD600 of 18 and the culture was grown for another 3 h until it reached an 
OD600 of 37. 
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Figure 3. SDS-PAGE and Western blot analysis of purified hGMCSF. Soluble fraction 
containing  TRX-hGMCSF  was  passed  through  Ni-NTA  column  and  the  fractions 
containing pure TRX-GMCSF were dialyzed and bound to Ni-NTA a second time in batch 
mode. The fusion protein was cleaved in the bound state with enterokinase enzyme in the 
presence  of  1  mM  CaCl2.  The  flow  through  containing  hGMCSF  was  collected  and 
analyzed. (a) SDS-PAGE showing different purification steps. Lane M: Molecular weight 
Marker;  lane  1:  Soluble  fraction  containing  TRX-hGMCSF  fusion;  lane  2:  Purified  
TRX-GMCSF fusion, lane 3: purified hGMCSF; (b) Immunoblot using mouse monoclonal 
anti-hGMCSF  antibody  to  confirm  the  identity  of  hGMCSF.  Lane  1:  Soluble  fraction 
containing TRX-hGMCSF fusion; lane 2: Purified TRX-GMCSF fusion; lane 3: purified 
hGMCSF. Arrows represent the purified hGMCSF in both SDS-PAGE and immunoblot. 
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Figure  4. Reverse phase chromatograph showing comparison of standard GMCSF and  
in-house purified hGMCSF with optimum mobile phase consisting of 0.1% TFA in 10% 
acetonitrile  (a)  and  0.1%  TFA  in  90%  acetonitrile  (b).  Flow  rate  was  maintained  at 
1 mL/min and detection was at 215 nm. Black line represents standard hGMCSF while red 
line indicates the in-house purified rhGMCSF. 
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Figure  5.  Size  Exclusion  HPLC  profile  of  standard  and  in-house  purified  GMCSF 
preparations. Size exclusion chromatograph showing comparison of standard GMCSF and 
in-house purified hGMCSF with optimum mobile phase consisting of 1.15 g di-sodium 
hydrogen  phosphate,  0.2  g  of  potassium  hydrogen  phosphate  and  23.4  g  of  sodium 
chloride. Flow rate was maintained at 0.5 mL/min and detection was at 215 nm. Black line 
represents standard hGMCSF while red line indicates the in-house purified rhGMCSF.  
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Figure  6.  The  biological  activity  of  in-house  hGMCSF  was  assessed  using  TF-1  cell 
proliferation assay. The activity data was analyzed statistically using Parallel Line Assay 
software  (PLA  2.0).  The  doses  are  indicated  on  the  horizontal  axis,  whereas  the 
corresponding responses are represented on the vertical axis. The individual responses for 
each treatment are symbolized by the red squares for the standard preparation and by the 
blue circles for the sample preparation.  
 
 
3. Experimental Section  
3.1. Cloning of hGMCSF in pET21a Vector and in pET32a as a TRX Fusion Tag 
The hGMCSF gene was amplified using a synthetic gene (GenScript, U.S.) by polymerase chain 
reaction using the oligos with reduced GC content, forward: 5’ CCG CCG GAA TTC GGA TCC GAT 
GAT GAT GAT AAA GCA (GGC) CCC (ACT) GCC (GTG) CGC (GCC) TCG (TGC) CCC (AGC) 
AGC (ATC) 3’ as and reverse: 5’ CCG CCG GAA TTC AAG CTT TCA CTC CTG GAC TGG CTC 
CCA 3’. The codons within brackets show the original sequence of the human GMCSF gene. PCR 
cycling conditions were: 94 °C  for 4 min followed by 5 cycles of 94 °C  for 30 s, 53 °C  for 30 s, 72 °C  
for 30 s and 25 cycles of 94 °C  for 30 s, 65 °C  for 30 s, 72 ° C for 30 s. The PCR product was cloned 
into  pET21a  as  an  NdeI/HindIII  fragment  and  into  pET32a  (Novagen,  U.S.)  as  a  BamHI/HindIII 
fragment and all the clones were confirmed by DNA sequencing.  Int. J. Mol. Sci. 2011, 12                       
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3.2. Expression of pET21a-rhGMCSF and pET32a-rhGMCSF in Shake Flask 
The pET21a-rhGMCSF and pET32a-rhGMCSF constructs were separately introduced into BL21 
(DE3)  codon  plus  cells  and  expression  was carried  out  at 37  °C  for 4 h in 100 mL Luria Broth 
containing 100 μg/mL ampicillin. The cells were induced with 1 mM IPTG and the induced cell pellet 
was suspended in 10 mM TrisCl, pH 8.0 followed by lysis by sonication (Sonics Vibracell, U.S.). 
Separation of soluble and insoluble fractions was carried out by centrifugation of the sonicated lysate 
at 13,000 rpm for 10 min and both the fractions were analyzed on SDS-PAGE followed by Coomassie 
blue staining.  
3.3. Bioreactor Studies  
The large scale fermentation was carried out in a 2 L bioreactor (Sartorius, Germany) with 2 L  
in-house media with 1% glycerol [27]. 2% of the overnight culture was used as inoculum and the 
culture was grown at 37 °C  and pH 7.0 up to an OD600 of 18. The cells were induced with 1 mM IPTG 
and the culture was grown for another 3 h until it reached an OD600 of 37. The culture media was 
centrifuged at 8000×  g for 10 min and the induced cell pellet was resuspended in 10 mM TrisCl  
pH 8.0. The suspension was subjected to cell disruption using a high pressure homogenizer (M/S Niro 
Soavi, Italy) at 800 to 900 bars for two passages. The homogenized cell lysate was centrifuged at 
12,500×  g for 15 min at 4 °C  to separate the soluble and insoluble fractions. 
3.4. Purification hGMCSF Using Ni
2+-NTA Column  
The cleared soluble fraction containing TRX-rhGMCSF was passed through Ni
2+-NTA column (GE 
Healthcare,  Sweden)  pre-equilibrated  with  10  mM  TrisCl,  pH  8.0  containing  10  mM  imidazole 
(Sigma, U.S.). After washing the column with equilibration buffer, the bound protein was eluted with a 
gradient  of  imidazole  (0.1–0.5  M).  The  elute  fractions  containing  the  majority  of  the  pure  
TRX-hGMCSF protein was dialyzed overnight against 10 mM TrisCl, pH 8.0 at 4 °C . For enterokinase 
reaction,  pure  TRX-hGMCSF  was  passed  through  a  second  round  of  purification  on  Ni
2+-NTA 
Sepharose that was pre-equilibrated with TrisCl, pH 8.0 in a batch mode in continuous motion in a 
rotating mixer. The bound fusion protein, was digested with bovine enterokinase (4.5 U/mg of pure 
fusion protein) (Novagen, U.S.) for four hours at room temperature in the presence of 1 mM CaCl2. 
The flow through was collected by centrifugation of the contents at 4400 rpm for 10 min and all 
samples were analyzed by SDS-PAGE followed by silver staining.  
3.5. Characterization of rhGMCSF by RP-HPLC 
The RP-HPLC was carried out using an ACE C18 (4.6 mm ×  150 mm) column on SHIMADZU  
LC-2010CHT  HPLC  system  provided  with  a  quaternary  pump,  a  thermostatted  autosampler,  a 
thermostatted column compartment, and a multiple wavelength ultraviolet (UV) detector. Data was 
collected and analyzed using LC Solution Software (Version 1.24). The mobile phase consisted of 
0.1%  TFA  in  10%  Acetonitrile  (A)  and  0.1%  TFA  in  90%  Acetonitrile  (B).  The  system  was 
equilibrated  with  a  mixture  A–B  (90:10)  until  a  stable  baseline  was  obtained.  Separations  were 
performed using a stepwise gradient in the following manner: from 10% to 65% mobile phase B over a Int. J. Mol. Sci. 2011, 12                       
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period of 20 min, followed by 65% to 100% mobile phase B over a period of 3 min. The flow-rate was 
maintained at 1.0 mL/min with detection at 215 nm at 30 ° C.  
3.6. Characterization of rhGMCSF by SE-HPLC 
SEC  was  performed  with  SHIMADZU  LC-2010CHT  HPLC  system  provided  with  a  quaternary 
pump, a thermostatted autosampler, a thermostatted column compartment, and a multiple wavelength 
ultraviolet (UV) detector. Data was collected and analyzed using LC Solution Software (Version 1.24). 
A  TSK-GEL  G3000SWXL  300 mm  ×   7.8 mm  column  (MW  range:  1000–500,000 Da)  (Tosoh 
Bioscience LLC, Montgomeryville, PA, U.S.) was chosen for the present studies. . The optimal mobile 
phase composition consisted of 1.15 g Di-sodium hydrogen phosphate, 0.2 g of Potassium hydrogen 
phosphate  and  23.4  g  of  sodium  chloride.  The  detector  was  set  at  215 nm  and  the  flow  rate  at 
0.5 mL/min. 
3.7. Western Blot Analysis 
Protein  samples  were  separated  on  denaturing  SDS-PAGE  and  transferred  to  nitrocellulose 
membrane. Immunoblot was performed using mouse monoclonal anti-hGMCSF antibody (Santacruz, 
U.S.)  followed  by  goat  anti-mouse  secondary  antibody  (Bangalore  Genei,  India).  The  blot  was 
developed using the substrate BCIP/NBT. 
3.8. Bioassay for hGMCSF  
TF-1 cells were maintained in RPMI-1640 with 10% FBS and 2 ng/mL rhGMCSF at 37 °C  in 
5% CO2. The cells were starved for 14–16 h in RPMI-1640 with 2.5% FBS. After starvation, the cells 
were plated in RPMI-1640 with 5% FBS at a seeding density of 1 ×  10
4 cells/well/50 µL. Standard and 
samples were added (50 µ L/well) at different concentrations and the plate was incubated for 48 h at 
37 °C  in 5% CO2. To each well, 20 µ L of MTS was added and amounts of formazan formed (an 
indicator of number of live cells, i.e., biological activity) were estimated by measuring OD490 after an 
additional 4 h of incubation. The ED50 value was determined and one unit of activity is defined as 
reciprocal of ED50. The data was analyzed statistically using Parallel Line Assay software (PLA 2.0), 
which  uses  three  tests  for  validity  of  the  assay:  test  of  regression,  test  of  linearity  and  test  of 
parallelism. This analysis gives  potency ratio that expresses the potency of the unknown sample in 
comparison to the potency of the standard. The graph was obtained by plotting responses against doses. 
4. Conclusions  
In this article, we report for the first time the hyper expression of hGMCSF in E. coli at shake flask 
level with a very high yield (~44 mg/L) which was easily scalable to ~400 mg/L in a bioreactor. Such 
a strategy of expressing rhGMCSF demonstrates the possibility of achieving high yield therapeutic 
proteins and could be applied to other therapeutic proteins. Int. J. Mol. Sci. 2011, 12                       
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